Previous studies have confirmed that eIF5A2 is upregulated in various cancer types, such as gastric cancer, bladder cancer, hepatocellular carcinoma (HCC), and colon cancer [28–32]. Here, EIF5A2 is linked to hepatocellular carcinoma.